With box warnings

Without box warnings

Branded

Generic

2 results

augtyro
(repotrectinib)
E.R. Squibb & Sons, L.L.C.
Usage: AUGTYRO is indicated for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) and for patients aged 12 and older with NTRK gene fusion-positive solid tumors that are advanced or metastatic, or where surgery poses severe risk, and have limited treatment options.
rozlytrek
(ENTRECTINIB)
Genentech, Inc.
Usage: ROZLYTREK is indicated for adults with ROS1-positive metastatic non-small cell lung cancer and for patients over 1 month old with NTRK gene fusion-positive solid tumors that are metastatic or not amenable to surgery. Approval for NTRK indication is accelerated, pending further clinical efficacy confirmation.

Medications for Solid Neoplasm With Neurotrophic Receptor Tyrosine Kinase Gene Fusion

augtyro